MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1253/circj.cj-22-0315

Медицинская библиотека · Circulation journal : official journal of the Japanese Circulation Society · 2022

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease - Insights From the REAL-CAD Study.

Natsuaki Masahiro, Morimoto Takeshi, Iimuro Satoshi, Fujita Retsu, Iwata Hiroshi, Miyauchi Katsumi, Inoue Teruo, Nakagawa Yoshihisa, Nishihata Yosuke, Daida Hiroyuki, Ozaki Yukio, Suwa Satoru, Sakuma Ichiro, Furukawa Yutaka, Shiomi Hiroki, Watanabe Hirotoshi, Yamaji Kyohei, Saito Naritatsu, Matsuzaki Masunori, Nagai Ryozo, Kimura Takeshi, REAL-CAD Investigators

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

It is unknown whether beneficial effects of higher-dose statins on cardiovascular events are different according to the thrombotic risk in patients with chronic coronary syndrome (CCS).

METHODS AND

RESULTS

The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study is a randomized trial comparing 4 mg and 1 mg pitavastatin in patients with CCS. This study categorized 12,413 patients into 3 strata according to the CREDO-Kyoto thrombotic risk score: low-risk (N=9,434; 4 mg: N=4,742, and 1 mg: N=4,692), intermediate-risk (N=2,415; 4 mg: N=1,188, and 1 mg: N=1,227); and high-risk (N=564; 4 mg: N=269, and 1 mg: N=295). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina. Cumulative 4-year incidence of the primary endpoint was significantly higher in the high-risk stratum than in the intermediate- and low-risk strata (11.0%, 6.3%, and 4.5%, P<0.0001). In the low-risk stratum, the cumulative 4-year incidence of the primary endpoint was significantly lower in the 4 mg than in the 1 mg group (4.0% and 4.9%, P=0.02), whereas in the intermediate- and high-risk strata, it was numerically lower in the 4 mg than in the 1 mg group. There was no significant treatment-by-subgroup interaction for the primary endpoint (P-interaction=0.77).

CONCLUSIONS

High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.

Для цитирования: Natsuaki Masahiro, Morimoto Takeshi, Iimuro Satoshi, Fujita Retsu, Iwata Hiroshi, Miyauchi Katsumi, Inoue Teruo, Nakagawa Yoshihisa, Nishihata Yosuke, Daida Hiroyuki, Ozaki Yukio, Suwa Satoru, Sakuma Ichiro, Furukawa Yutaka, Shiomi Hiroki, Watanabe Hirotoshi, Yamaji Kyohei, Saito Naritatsu, Matsuzaki Masunori, Nagai Ryozo, Kimura Takeshi, REAL-CAD Investigators. Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease - Insights From the REAL-CAD Study.. Circulation journal : official journal of the Japanese Circulation Society. 2022. DOI: 10.1253/circj.cj-22-0315.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.